US equities |
SPCX $166.97 ▲+5.04% NVDA $236.85 ▲+1.24% MU $1,063.94 ▼-1.02% TSLA $377.77 ▲+1.94% MSFT $526.57 ▲+1.75% SNDK $1,714.93 ▼-0.29% INTC $116.69 ▼-2.21% META $745.64 ▲+2.41%
FinancialContent

Articles published by Egle Therapeutics

News headline image
Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study
From Egle Therapeutics
Via GlobeNewswire
News headline image
Egle Therapeutics to Present Clinical Data at the Upcoming European Academy of Dermatology and Venereology (EADV) Congress in Vienna
From Egle Therapeutics
Via GlobeNewswire
News headline image
Egle Therapeutics and Consortium Partners Awarded €8 Million Grant from Horizon Europe to Advance Clinical Development of EGL-001 in Neoadjuvant Head and Neck Cancer
From Egle Therapeutics
Via GlobeNewswire
News headline image
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
From Egle Therapeutics
Via GlobeNewswire
Tickers SNSE
News headline image
Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis
From Egle Therapeutics
Via Business Wire
News headline image
Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting
From Egle Therapeutics
Via Business Wire
News headline image
Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030
From Egle Therapeutics
Via Business Wire
News headline image
Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer
From Egle Therapeutics
Via Business Wire
News headline image
Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting
From Egle Therapeutics
Via Business Wire
News headline image
EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures
From EGLE Therapeutics
Via Business Wire
News headline image
Egle Therapeutics Strengthens its Leadership Team with the Appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer
From Egle Therapeutics
Via Business Wire
News headline image
Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers
From Egle Therapeutics
Via Business Wire